Gaithersburg, Maryland – February 5, 2020 : MaxCyte, the global cell-based therapies and life sciences company, announces its planned participation at the BIO CEO & Investor Conference at the New York Marriott Marquis. CEO & President Doug Doerfler will present Monday, 10 February at 2:30 p.m. ET (Odets Room) on how MaxCyte is driving the development of the next generation of cell-based therapies through its ExPERT™ instrument family, supporting its Life Sciences Business, and with its proprietary CARMA platform.
The ExPERT instrument family represents the next generation of the industry’s leading, clinically validated, electroporation technology for complex and scalable cellular engineering. By delivering high transfection efficiency with enhanced functionality, the ExPERT platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics and provides a single discovery and development platform from concept to clinical development to commercialization. In 2019, the Company signed five clinical/commercial licenses with partners including Kite (Gilead), Editas Medicine, Vor Biopharma and KSQ Therapeutics, and now has more than 100 cell therapy programmes under license of which more than 70 are licensed for clinical use.
CARMA Cellular Therapies is developing its novel and proprietary technology for non-viral, human messenger RNA (mRNA)-based, chimeric antigen receptor (CAR) or T-cell receptor (TCR) redirected immune cell therapies for solid cancer and offers the potential for a safer cell therapy, as a result of transient expression of receptor(s) and a non-viral delivery approach. MaxCyte recently established its CARMA program as a wholly owned subsidiary to facilitate independent investment and new partnerships to advance the CARMA platform.
For a meeting with MaxCyte’s CEO at the conference please contact Sheila Tiffany at email@example.com.
MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. Through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its technology worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 100 partnered programme licenses in cell therapy with more than 70 licensed for clinical use. The Company has now signed eight clinical/commercial licenses with leading cell therapy developers. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. MaxCyte is also developing novel CARMA therapies, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte’s mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. MaxCyte has established CARMA as a wholly owned subsidiary to facilitate independent investment and new partnerships to advance the CARMA platform. For more information, visit www.maxcyte.com
For further information, please contact:
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer
|+1 301 944 1660|
|Financial PR Adviser
Consilium Strategic Communications
+44 (0)203 709 5700
|US Media Relations
|+1 410 299 3310